Novartis India Ltd Stock Analysis

BSE: 500672 | NSE: NOVARTIND | Trading | Small Cap

BSE Share Price 29-Nov-2022 13:31
676.00 2.45 (0.36%)

DeciZen - Make an Informed Decision on Novartis

Overall Rating

1. Quality

2. Valuation

Overvalued

3. Price Trend

Semi Strong

Novartis Price Chart

P/E Ratio (SA) :
30.96
Market Cap :
1,663.1 Cr.
52-wk low :
566
52-wk high :
848
Bole Toh?

1. Is Novartis India Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Novartis India Ltd is a below average quality company.

2. Is Novartis India Ltd undervalued or overvalued?

The key valuation ratios of Novartis India Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Novartis India Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Novartis India Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Novartis:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Novartis India Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
ROCE % 14%10.7%7.6%18.1%5.4%8.3%4.5%2.2%3.2%4.9%-
Value Creation Index 0-0.2-0.50.3-0.6-0.4-0.7-0.9-0.8-0.7-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 903862873690656564491438381400420
YoY Gr. Rt. %--4.6%1.3%-21%-4.9%-14.1%-13%-10.7%-13%4.9%-
Adj EPS 37.63123.262.120.226.213.34.67.212.621.8
YoY Gr. Rt. %--17.6%-25.2%167.6%-67.5%29.8%-49.4%-65%55.2%74.6%-
BVPS (₹) 281.7300.8313.5375.6329.5299.8309.3293.4289.4281.2299.2
Adj Net Profit 12099.274.219956.864.732.711.517.83154
Cash Flow from Ops. 7.4-4.6-59.656.6-40.8161-194-23.1-69.238.7-
Debt/CF from Ops. 0-000000000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -8.7%-9.4%-6.6%4.9%
Adj EPS -11.5%-9%-1.7%74.6%
BVPS 0-3.1-3.1-2.8
Share Price -0% 0.9% 0.5% -10.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
Return on Equity % 1410.77.618.15.47.84.41.62.54.47.5
Op. Profit Mgn % 9.9-0.2-0.94.63.7-1.43.23.16.86.414.4
Net Profit Mgn % 13.311.58.528.88.711.56.72.64.77.812.8
Debt to Equity 00000000000
Working Cap Days 7268196673984296888446758911,170664
Cash Conv. Cycle 1625293026-7-20-548484

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 7.50%

Sales growth has been subdued in last 3 years -6.59%

Net Profit has been subdued in last 3 years -1.74%

Sales growth is not so good in last 4 quarters at 6.24%

Latest Financials - Novartis India Ltd.

Standalone Consolidated
TTM EPS (₹) 21.8 -
TTM Sales (₹ Cr.) 420 -
BVPS (₹.) 299.2 -
Reserves (₹ Cr.) 726 -
P/BV 2.25 -
PE 30.96 -
From the Market
52 Week Low / High (₹) 566.00 / 848.00
All Time Low / High (₹) 65.00 / 1436.35
Market Cap (₹ Cr.) 1,663
Equity (₹ Cr.) 12.4
Face Value (₹) 5
Industry PE 101.5

Management X-Ray of Novartis :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Novartis

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)

News

Novartis India Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Novartis on 29-Nov-2022 13:31 is : 676.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 29-Nov-2022 13:31 the market cap of Novartis stood at ₹ 1,663.1.
The latest PE ratio of Novartis as of 29-Nov-2022 13:31 is 30.96.
The latest PB ratio of Novartis as of 29-Nov-2022 13:31 is 2.25
The 52-week high of Novartis is ₹ 848.0 and the 52-week low is ₹ 566.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Novartis is ₹ 419.7 ( Cr.) .

About Novartis India Ltd

Novartis was created in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its predecessor companies trace roots back more than 250 years, with a rich history of developing innovative products. From beginnings in the production of synthetic fabric dyes, the companies that eventually became Novartis branched out into producing chemicals and ultimately pharmaceuticals.

The history of Novartis traces the converging destinies of three companies: Geigy, a chemicals and dyes trading company founded in Basel, Switzerland in the middle of the 18th century; Ciba, which began producing dyes in 1859; and Sandoz, a chemical company founded in Basel in 1886.

These companies shared a common trait which lives on at Novartis: a passion for developing and marketing new products that contribute to human progress through advances in science and health. Building on this heritage, today Novartis focuses its innovation prowess on addressing the unmet needs of patients worldwide.

Since 1947, Novartis has had a significant footprint in India - committed to drug development, manufacturing, commercial and social business services. It has three legal entities namely, Novartis Healthcare Private Limited, Novartis India Limited and Sandoz Private Limited employing thousands of people. It has a rich portfolio of both innovative and established medicines addressing various therapeutic needs: cardiovascular, eye care, immunology and dermatology, metabolics, neuroscience, oncology, respiratory and organ transplant, to meet the medical needs of patients in India.

Its social business -- Arogya Parivar -- is expanding access to community education, improved infrastructure and affordable healthcare products for underserved populations in rural India.

The company’s purpose is to reimagine medicine to improve and extend people’s lives. It uses innovative science and technology to address some of society’s most challenging healthcare issues. It discover and develops breakthrough treatments and find new ways to deliver them to as many people as possible. It also aims to reward those who invest their money, time and ideas in the company.

Business area of the company

As a science-based and patient-oriented healthcare company, it strives to be a global leader in growing areas of healthcare. Following a corporate transformation Novartis globally is focused on three divisions with global scale and innovation power - pharmaceuticals, eye care and generic medicines. This has strengthened the future growth prospects of the company.

In India, the Pharmaceutical business of Novartis India Limited is focused on Bone & Pain, Calcium portfolio, Gynecology and Neurosciences and the Generics business is focused on Gynecology, Anti-TB and Anti-infectives.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now